Pod Insights Pharmacy Podcast Network Tariffs, Trade, and Turbulence: Navigating the Impact on Pharmacy | Tech Trends: PrimeRx About this episode In this episode of the PrimeRx Podcast, David Kirkus breaks down one of the most pressing challenges facing today’s pharmacy industry—pharmaceutical tariffs. With increasing trade tensions and new policies taking shape, pharmacies across the country are bracing for the potential ripple effects on drug pricing, supply chain stability, and patient access. David unpacks how tariffs on imported Active Pharmaceutical Ingredients (APIs) and finished medications—especially from countries like China and India—are creating vulnerabilities in a system already strained by global disruptions. Listeners will gain a practical understanding of how these policies could impact everything from acquisition costs and pricing models to patient outcomes and inventory reliability. The conversation also highlights regulatory and legislative responses, and what pharmacies can do now to prepare. From strategic sourcing to investing in automation and domestic partnerships, David offers clear-eyed guidance for navigating today’s trade turbulence.
Transcript 0:05 Speaker 00 You are listening to the global network of podcasters dedicated to the pharmacy profession. Welcome to the Pharmacy Podcast Network.
0:27 Speaker 01 We are committed to the pharmacy owner's success. PrimeRx believes in empowering pharmacies with innovative solutions to thrive in today's competitive landscape. We look forward to working with pharmacy owners and sharing how our solutions can contribute to their sustained profitability and growth. Connect with us on the web by going to primerx.io. That's primerx.io.
0:50 Speaker 02 Hey there. This is Todd Urie, founder of the Pharmacy Podcast Network, bringing you another Pharmacy Podcast Tech Trends from the team at PrimeRx. And today is a necessary topic. It's something that we definitely want more information on. It's, I always want to demystify things and I like having people in position to bring us information that we can rely on and go back to as business owners, as pharmacy owners, and be like, okay, this is good. At least it gets the latest in the, in the subject. And the subject is the tariffs and how is a tariff going to impact all of us?
1:34 Speaker 02 How's it going to impact the independent community pharmacy and our wholesaler relationships and technology? So today it's tariffs, trade, and turbulence, navigating the impact on pharmacy. And my guest is a returning Pharmacy Podcast Network guest, David Kirkus. He's Vice President of Market at PrimeRx. David, it is great to have you back.
1:57 Speaker 03 Thanks, Todd. Great to be back with you again.
2:00 Speaker 02 All right, so new developments surrounding pharmaceutical tariffs. We have news that is, it's fresh. And if you haven't seen it, just on the 19th of the month on PharmaVoice, it's, the PharmaVoice publishes, and it's titled "Tracking a Moving Target: Drugmakers Break for Looming Tariff Impact and With Policies in Flux, Companies Seek to Be Proactive and Understand Their Supply Chain." This is a great article. We're going to have this in the show notes. We're going to have a link to this article in the show notes, and definitely take a read to that. But I want to shift it over to you first, David.
2:43 Speaker 02 Kind of just, let's get some things out of the way. Let's slow down for a second. Like I said, I like to demystify. So, right out of the gate, let's, let's get a brief overview of the current state of pharmaceutical tariffs, from your perspective.
2:57 Speaker 03 Sure. Yeah, it seems to be a moving target over the last few weeks, with a lot of things in flux. And uncertainty, I think, for everybody potentially impacted by pharmaceutical tariffs is, is top of mind right now. And how do we react in an uncertain time is going to be really critical over the next several months for pharmacies and everyone else impacted across the entire drug chain, in, supply chain in the U.S. So, the proposed tariffs would impact imported finished drugs or active pharmaceutical ingredients. This comes from Commerce Department Insights citing national security concerns around the
3:41 Speaker 03 excessive reliance we have in the U.S. on, on foreign-produced pharmaceuticals. About 90% of generic drugs are manufactured abroad, primarily in India and China. And that reliance, you know, comes with exposure. It makes our, our supply chain more fragile than we'd like it to be, and exposed to global disruptions, potentially.
4:07 Speaker 03 So let's keep in mind that these tariffs have been floated as an idea. It's a policy proposal. There is no timeline. There's really no framework and structure that we can use to guide us at this current point. So we'll have to continue to monitor how the administration moves forward over the next several weeks. But subsequent to the announcement of proposed tariffs, we also had on May 12th, a new executive order issued that establishes most favored nation pricing and requires the U.S. to pay no more than the lowest price paid by peer nations for the same drug. So a lot of really sort of blunt macroeconomic tools that the administration is proposing,
4:51 Speaker 03 aimed primarily at bringing production back to the U.S. and then also lowering drug costs. I think these are very well-intended policy proposals, but potentially very destabilizing in the short term. I think, before we move to, I think it's also important to note that drug pricing, it always mystifies me how much attention that drug pricing commands from both politicians and media sources. Prescription drugs account for less than 10% of the total U.S. healthcare spending and provide lifesaving treatments. They decrease the overall cost of healthcare.
5:32 Speaker 03 There's plenty of evidence that more utilization of drugs, better adherence to medications that patients are on, will further decrease the overall cost of healthcare. So I think it's a bit unfortunate that pharmaceutical pricing commands as much attention as it does, but because it does, we are all affected by these policy decisions. And as always, pharmacy tends to find itself in the middle and exposed in a variety of different directions.
6:05 Speaker 02 I'm glad you mentioned that. There are, we could start slicing the pie around the impact of tariffs on different portions of the ecosystem. And not only do companies have to know where the products are coming from, but they also have to determine that country of origin for the ingredients, which is not always straightforward. And I think of where the API was manufactured, but it can shift to that finished dose if there's a substantial transformation, which can occur when products contain multiple APIs. And that was mentioned in the PharmaVoice article, and it comes down to that supply chain disruption. So how are tariffs, how do they affect the importation,
6:48 Speaker 02 importing of active pharmaceutical ingredients in those finished drugs?
6:54 Speaker 03 Well, I think tariffs in the pharmaceutical industry is new, right? This is not traditionally the way that the United States treats pharmaceutical manufacturers. So I think we have a couple of things we can look at is the way that tariffs have impacted other industries where they have been imposed. And what you see in the short term is typically increased pricing and supply disruption. And I don't see how we would avoid either of those in a world where, you know, immediate tariffs of significant amounts
7:35 Speaker 03 are imposed on pharmaceutical ingredients and finished products. The reason is very simple. It's the pharmaceutical manufacturing industry exists to produce drugs and sell them profitably wherever they're selling them. And if their costs increase, they are going to pass those costs on and remain profitable producing the pharmaceuticals that they're producing, one way or the other. And if that means passing on the cost, that's going to lead to a rise in costs for those drugs in the US in the short term. The other potential consequence is rationalization of production lines where
8:19 Speaker 03 lower margin products, pharmaceutical manufacturers in India, for instance, are not going to be thinking about the long-term impact on supply and availability in the US. They're thinking about which product lines that my teams are producing are generating the most profit for my company. And when those profits are impacted, they will very easily stop producing drugs and shift production to others where they can better manage the financial impacts to their own businesses. So, think all the way down to the pharmacy counter, what do those impacts look like? I think it's a combination of generics, in particularly, having a lot
9:03 Speaker 03 of volatility around pricing.
9:05 Speaker 02 Yep.
9:06 Speaker 03 And further enhanced by disruptions to supply, making it more difficult to find the drugs that pharmacies need, particularly if they're shopping in a single source.
9:17 Speaker 02 Yeah, I also think, so, we want, based on these tariffs, the administration is saying, hey, we want more production happening here at home. We want it to be from the United States. And that's great. But to stand up a manufacturing plant in the United States, you do need FDA approval. And I'm wondering, will the FDA expedite and start concentrating on getting more authorization in place for manufacturers that are like bringing things
9:53 Speaker 02 back? I think of my own, you know, my own community of southwestern Pennsylvania, and we have a rich source of generic.
10:08 Speaker 02 Creation right here in southwestern Pennsylvania with several industrial parks that have pharmaceutical generic manufacturers in them. And one of them that was close in Cannonsburg, which moved, moved overseas. And that was seven to nine years ago. And I'm wondering, does this, does this create a resurgence where they come back and begin manufacturing again? Because they, if you think of the employee access of an entire environment or of a, you
10:47 Speaker 02 know, the southwestern Pennsylvania region, the Pittsburgh region, has this huge source of employees that could really jump in immediately. But what do you think of those other stipulations that would, that we're going to have to expedite in order to, you know, in order to start manufacturing here at home?
11:08 Speaker 03 Yeah, it's certainly not something that we can ramp up and scale to the current level of international production over, over months. It's certainly a years-long process to move an entire industry from a foreign source to a US-based source. I think, again, the intention is, is very aspirational and certainly, long-term, the right thing to do for the US economy and the, and the US healthcare system as a whole. I just think that, you know, that gap between where we are now and where we would like to be is, is very difficult to cross. It's a very complex industry.
11:53 Speaker 03 And it's going to be resisted from a lot of different avenues. I think you're going to see litigation, slowing processes, and potentially turning this into something that could linger for some time before we, we arrive at that sort of nirvana state where the US is reliant on itself to supply pharmaceuticals.
12:17 Speaker 03 So yeah, I think going back to where I started, I think uncertainty is going to be the most, I think we are going to live in a time of uncertainty for the drug supply chain until there's some clarity around, you know, is tariffs a tool that the administration is proposing to generate negotiation to land somewhere, a little bit softer landing somewhere in the short term that then combines with either tax incentives or other incentives that are used to bring more production onto the US shore. But I certainly, you know, hope that we don't end up in a position where pharmacies continue to struggle, continue
13:02 Speaker 03 to fight challenges on reimbursement and availability of products. And, you know, we're already seeing so many pharmacies struggling today to just keep their head above water. I don't see a lot of good here in the short term, unfortunately. I think it makes it even more important than ever for pharmacies to optimize their cost of goods. It's the one lever left that pharmacies really have any control over at all. And so, yeah, we'll talk a bit in a moment, I hope, about what Primark is doing to help.
13:35 Speaker 02 Absolutely. The next subject that I want to make sure listeners, you know, get some information from because this is going to come up in their minds as they're listening is the shortages that this could create around chemotherapy drugs and pain relievers and antibiotics, ADHD medications. Those are one of the top seven that are listed right now that are going through some shortage issues. 300-plus NDCs are on the shortage list. So when I think of the tariff issue and impacts, it's going to be impacting our shortage issues too. So definitely give us your thoughts on shortages and accessibility.
14:20 Speaker 03 Absolutely agree, yes. Like I mentioned earlier, the pharmaceutical manufacturers are not going to continue to produce drugs just for the benefit of the US healthcare system. It has to be financially rewarding for them to continue to produce those drugs. And when they're not, then the easiest thing for them to do is to shut down production lines and move those production lines to more profitable drugs. That is, in large part, what drives drug shortages in the environment we already live in without tariffs. So tariffs, essentially raising the cost of production for pharmaceutical manufacturers in other countries, is going
15:00 Speaker 03 to have to lead to them shifting those costs or discontinuing those product lines. And when a major manufacturer, or multiple major manufacturers of some of the top-spuised medications in the US stop producing those drugs, we don't have an easy place to go to backfill that supply. So I do think that unfortunately, drug shortages will continue to remain at least at the level they're at now. And if tariffs are implemented at the rate proposed, then they could potentially become even much more of a problem.
15:41 Speaker 02 Agreed. Agreed. So there's policy and regulations that we're going to be waiting on to really gel, and having to wait on something, having to wait on PBM reform, or having to sit around and wait for policy to kind of really become something beyond the hyperboil that could be on either side of the argument of good tariffs, bad tariffs, things that we cannot control, David. Goodness gracious, we can't control that. But I love the speculation. I love the insights, because it's butted up against data and things that we have to
16:20 Speaker 02 really dig down into for our pharmacy owner listeners. But we do have control over something. And that's next. So let's shift gears. We're talking about the tariffs, and the tariffs' impact on my pharmacy business, my impact on my accessibility for my patients to the medication, the impact on pricing, profitability, obviously.
16:44 Speaker 02 We can control some things through market and that was the reason that you came on the show originally in the first of the year, beginning of 2025. And now we have more and more of our pharmacy owners engaging. You have transactions to show that there is in fact an impact on savings and on monthly savings. So let's shift that gear and talk about what pharmacy owners can do right now that they are in control of through the market system.
17:16 Speaker 03 Yeah, thanks, Todd. And just I want our pharmacy owners and operators to just think about the fact that within the world of PBM-dominated reimbursement for pharmaceuticals, pharmacy owners don't have the ability to shift costs anywhere. The reimbursement is controlled by the terms of an agreement you have with a PBM. When prices come down, reimbursement comes down. It happens rather quickly and you're making the same margin percentage on a smaller number and your profitability declines slightly as price comes down. On
17:59 Speaker 03 the other end, PBMs have been notoriously slowed update reimbursement rates when prices rise. And this leaves pharmacies exposed while their prices go up and they're still being paid based on outdated price benchmarks. So really, from my standpoint, the most important thing that pharmacy operators can control is your cost of goods. It's the most immediate actionable lever that you have. The era of single supplier loyalty really has to come to an end. Most pharmacies buy most of their drugs from a single source and that completely eliminates competition from driving prices in their favor. Competition does drive savings.
18:43 Speaker 03 Diversification is really the only way to stay agile while you're facing drug shortages or while price volatility is impacting your business.
18:54 Speaker 03 We see pharmacies today using PrimeRx Market. We've got 50 vetted wholesalers in one place that you can shop across. Those wholesalers, they come onto our marketplace and they have to compete on price and they have to compete on availability. And these are the two biggest factors facing pharmacies in an uncertain time with looming tariffs that you need to be in the driver's seat. You have to control your own destiny and not be reliant on macroeconomic changes that you can't control. Pharmacies today are saving tens of thousands of dollars a year. Literally, we have pharmacies saving hundreds of thousands of dollars a year on their cost
19:35 Speaker 03 of goods just by shifting a portion of their purchasing to a more competitive source. And I think today, it's time to adapt. Doing the things that we've always done in pharmacy, the way we've always done them, it just is not working anymore. The pharmacy that's going to continue to survive and thrive in this uncertain marketplace that we operate in is the one that adapts in real time, drug by drug. Adaptability is the way to control margin. And we're helping pharmacies adapt and survive at PrimeRx.
20:08 Speaker 02 If you're listening, I just want you to pay attention. There are links in your show notes, but if you just want to type this in, if you're in front of your desktop, just type in primrex.io/market. Once again, that's primrex.io/market. If you are driving or doing something, don't worry, the link will be in the show notes. And David, what's actionable is that means they can do this today. They can set up an account, they can register under 10 minutes. It's easy to start making some comparisons. And tell them about the whopping cost of what this cost them to.
20:45 Speaker 03 Yeah, it will cost you an enormous amount of $0 to join the PrimeRx Marketplace. It is free to our pharmacy buyers. And it absolutely provides immediate access to, like I said,
21:02 Speaker 03 almost 50 wholesalers, full-line wholesalers, brands, generics, OTCs, controlled substances, medical devices, you name it. Mostly, most of the products that a pharmacy needs, either behind the counter or over the counter, you're going to find on the market, and you're going to find it competitively priced, and you're going to find it in good supply from well-known, trusted wholesalers.
21:28 Speaker 02 David, I want to just say thank you on behalf of our listeners and myself, bringing us content that is really not only updating and demystifying what is tariffs, how are tariffs going to impact us? But giving us another solution of another option of how to save some money so that we can be profitable and not just surviving, but thriving as pharmacies. And it's harder than ever to do so, but having tools like this is pretty important. So, thank you so much for being part of another podcast. Or, I don't know, you're going to come back for the triple, for the triple hit?
22:03 Speaker 03 Absolutely, yeah. I'm happy to talk pharmacy with you anytime, Todd.
22:07 Speaker 02 Well, I love it. You are listening to the Pharmacy Podcast Network's coverage of trends in pharmacy with PRX. They've been a great resource partner in really driving quality knowledge with the Pharmacy Podcast Tech Trends, prescribing knowledge and dispensing wisdom in every episode. Thank you so much for listening. Subscribe on all platforms, Spotify, Apple, anything that you have for a preface, and take a look at primerx.io/podcasts for the entire library. Once again, that's primerx.io/podcasts. And David, we will talk with you next time.
22:49 Speaker 03 Thanks, Todd.
Previous Solving Tomorrow’s Challenges Today: Innovating Pharmacy Care with LTC@Home, HealNow & GRX Marketing | Marketing Vitals Next Beyond the Supply Agreement | Future-Ready Your Pharmacy with IPC Page updated November 15, 2026 · transcript and summary are machine-generated